AMYT Key Statistics, Chart & Performance
The current stock price of AMYT is 14.7 USD. In the past month the price increased by 1.03%. In the past year, price increased by 86.55%.
AMYT Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to AMYT. When comparing the yearly performance of all stocks, AMYT is one of the better performing stocks in the market, outperforming 96.95% of all stocks.
AMYT Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
AMYT Forecast & Estimates
7 analysts have analysed AMYT and the average price target is 36.48 USD. This implies a price increase of 148.2% is expected in the next year compared to the current price of 14.7.
AMYT Ownership
AMYT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.22 | 981.68B | ||
| JNJ | JOHNSON & JOHNSON | 21.07 | 526.82B | ||
| MRK | MERCK & CO. INC. | 12.35 | 270.12B | ||
| PFE | PFIZER INC | 8.02 | 145.84B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.42 | 112.50B | ||
| ZTS | ZOETIS INC | 19.66 | 54.93B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.62 | 22.83B | ||
| VTRS | VIATRIS INC | 5.52 | 14.81B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.55 | 12.19B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.94B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.31B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.41B |
Related stock screener links
About AMYT
Company Profile
Amryt Pharma Plc is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. The firm is focused on developing and commercialization of treatments for orphan and rare diseases patients. The Company’s commercial business provides orphan disease products, which includes Juxtapid/ Lojuxta and Myalept / Myalepta. The Company’s lead development candidate is FILSUVEZ.
Company Info
AMRYT PHARMA PLC - SPNR ADR
Ivybridge House, 1 Adam Street
London D02 CR98 GB
CEO: Dr. Joseph A. Wiley
Employees: 99
Phone: 442034155730.0
AMRYT PHARMA PLC - SPNR ADR / AMYT FAQ
What does AMRYT PHARMA PLC - SPNR ADR do?
Amryt Pharma Plc is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. The firm is focused on developing and commercialization of treatments for orphan and rare diseases patients. The Company’s commercial business provides orphan disease products, which includes Juxtapid/ Lojuxta and Myalept / Myalepta. The Company’s lead development candidate is FILSUVEZ.
Can you provide the latest stock price for AMRYT PHARMA PLC - SPNR ADR?
The current stock price of AMYT is 14.7 USD. The price increased by 0.07% in the last trading session.
Does AMRYT PHARMA PLC - SPNR ADR pay dividends?
AMYT does not pay a dividend.
How is the ChartMill rating for AMRYT PHARMA PLC - SPNR ADR?
AMYT has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What do analysts say about AMRYT PHARMA PLC - SPNR ADR (AMYT) stock?
7 analysts have analysed AMYT and the average price target is 36.48 USD. This implies a price increase of 148.2% is expected in the next year compared to the current price of 14.7.
Is AMRYT PHARMA PLC - SPNR ADR (AMYT) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AMYT.